Combretum leprosum Mart. (Combretaceae): Potential as an antiproliferative and anti-inflammatory agent  by Horinouchi, Cíntia Delai da Silva et al.
Journal of Ethnopharmacology 145 (2013) 311–319Contents lists available at SciVerse ScienceDirectJournal of Ethnopharmacology0378-87
http://d
n Corr
Cieˆncias
Grossa,
E-mjournal homepage: www.elsevier.com/locate/jepCombretum leprosum Mart. (Combretaceae): Potential as an antiproliferative
and anti-inﬂammatory agentCı´ntia Delai da Silva Horinouchi a, Daniel Augusto Gasparin Bueno Mendes a, Bruna da Silva Soley a,
Evelise Fernandes Pietrovski a, Valdir Alves Facundo b, Adair Roberto Soares Santos c, Daniela
Almeida Cabrini a, Michel Fleith Otuki d,n
a Laboratory of Inﬂammation, Department of Pharmacology, Universidade Federal do Parana´, PO Box 19031, CEP 81530-900 Curitiba, PR, Brazil
b Department of Chemistry, Universidade Federal de Rondoˆnia, CEP 76801-974 Porto Velho, RO, Brazil
c Department of Physiological Science, Universidade Federal de Santa Catarina, CEP 88040-900 Floriano´polis, SC, Brazil
d Department of Pharmaceutical Sciences, Universidade Estadual de Ponta Grossa, CEP 84030-900 Ponta Grossa, PR, Brazila r t i c l e i n f o
Article history:
Received 29 June 2012
Received in revised form
26 October 2012
Accepted 28 October 2012
Available online 16 November 2012
Keywords:
Combretum leprosum
Combretaceae
Skin diseases
Inﬂammation41 & 2012 Elsevier Ireland Ltd.
x.doi.org/10.1016/j.jep.2012.10.064
espondence to: Universidade Estadual de Pon
Farmaceˆuticas, Laborato´rio de Cultivo Celula
PR-Brazil. Tel.: þ55 42 32203120.
ail address: michelotuki@yahoo.com.br (M.F.
Open access undea b s t r a c t
Ethnopharmacological relevance: Combretum leprosum is a species that is popularly used in Brazil as a healing
agent to treat skin problems and lesions. In this study we investigated the possible potential of this extract to
treat inﬂammatory and hyperproliferative skin conditions.
Materials and methods: Classical models of skin inﬂammation such as TPA- and croton oil-induced mouse
ear oedema were applied in order to verify the potential topical anti-inﬂammatory activity of the ethanolic
extract from ﬂowers of Combretum leprosum.
Results: Topical application of ethanolic extract promoted a dose-dependent inhibition of phorbol ester-
induced ear oedema, reduced myeloperoxidase activity and IL-6 tissue levels with inhibition comparable to
dexamethasone (positive control). Histological and immunohistochemical analysis revealed that ethanolic
extract also suppressed cell inﬁltration. Ethanolic extract altered inﬂammatory parameters on a chronic skin
inﬂammation model induced by repeated applications of croton oil, decreasing ear oedema, epidermal
hyperproliferation and cell inﬁltration. In addition, immunohistochemical analysis showed that the extract
decreased PCNA expression on the epidermis.
Conclusion: Taken together, these results suggest that the extract from ﬂowers of Combretum leprosum could
be considered as a new potential tool for the treatment of several skin inﬂammatory diseases since it
reversed the skin inﬂammatory and hyperproliferative process in a very signiﬁcant manner. Further
investigations are needed in order to verify the cellular mechanism and safety of Combretum leprosum extract.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Skin is the body organ responsible for a direct interaction
between the environment and the organism, since it is localised
on the body surface. Therefore, its main function is to form an
effective barrier protecting the organism from several external
stimuli, such as pathological agents, processes and events. Thus,
as a mechanism of defence, the skin is able to recognise,
discriminate, and integrate speciﬁc signals from the environment
and generate appropriate responses aimed at preserving body
homeostasis (Debenedictis et al., 2001). However, this response is
usually marked with the presence of pro-inﬂammatory mediators
which are released by skin cells promoting an inﬂammatoryta Grossa. Departamento de
r. Uvaranas 84030-900-Ponta
Otuki).
r the Elsevier OA license. process which can cause inﬂammatory skin diseases when it is
not properly controlled (Serhan and Petasis, 2011).
Skin disorders can be initiated by either exogenous or endo-
genous stimuli and usually are marked by a disruption of the
barrier, sensitisation, inﬂammation, changes in epidermal prolif-
eration and differentiation (Proksch et al., 2008). The most
common inﬂammatory dermatoses are psoriasis and atopic der-
matitis, which have a high impact on the patient’s life. Psycholo-
gical disturbances, such as embarrassment, worry, stigmatisation,
depression, and problems with self-esteem and body image are
very common in dermatological patients. All of these feelings can
impair several aspects of life, such as personal relationships,
sports, sexuality, self-care actions, and activities at work or school
(Tejada Cdos et al., 2011).
Most of the chronic skin inﬂammatory conditions, such as
psoriasis, have no aetiology or pathophysiology elucidated. Thus,
current therapeutic treatments are not effective or can show
undesirable side effects when effective. The lack of ideal therapy
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ventions which could prevent oedema, plasma extravasation, and
the recruitment of inﬂammatory mediators to combat excessive
inﬂammatory reactions (Stern et al., 2004). An interesting alter-
native would be the use of medicinal plants that have been used
since ancient times to treat skin disorders and wounds. As well
as presenting a cheaper and easily accessible alternative when
compared with synthetic medicines, studies have proven the
effectiveness of medicinal plants with regard to altering immune
functions and modulating inﬂammatory processes without caus-
ing side effects such as immunosuppression (Plaeger, 2003;
Saklani and Kutty, 2008). In fact, some medicinal plants, such as
Aloe vera (Aloe barbadensis) and the Chinese herb indigo naturalis
(Baphicacanthus cusia), have been employed in clinical trials
and have demonstrated efﬁcacy comparable to the drugs cur-
rently used in the treatment of psoriasis (Choonhakarn et al.,
2010; Lin et al., 2008). Furthermore, several plant-derived com-
pounds are established in dermatologic therapy, as seen with
dithranol, an anthracene derivative isolated from Andira araroba,
which shows great efﬁcacy when employed as an anti-psoriatic
therapy (Reuter et al., 2010).
Combretum leprosum Mart. (Combretaceae) is a species that is
commonly found in northeast Brazil where it is popularly known
as ‘‘mufumbo’’ (Lira et al., 2002). Several parts of this plant, such
as the leaves and ﬂowers, are used in folk medicine as a healing
agent, for the prevention of rashes, and to clean wounds. In
addition, the plant is also used for the containment of bleeding,
and as a sedative, anti-diarrhoeal, expectorant, and antitussive
(Agra et al., 2007; De Albuquerque et al., 2007). Pharmacological
studies with extracts and isolated compounds from different parts
of the plant suggested that the biological activities of Combretum
leprosum include anti-inﬂammatory, antinociceptive, anticholi-
nesterase and anti-ulcerogenic effects (Facundo et al., 2005;
Nunes et al., 2009; Pietrovski et al., 2006). According to phyto-
chemical analysis, Combretum leprosum is rich in compounds such
as cycloartanes, triterpenes (arjunolic and mollic acid, and
3b,6b,16b-trihidroxilup-20(29)-ene), and ﬂavonoids (3-O-meth-
ylquercetin, and quercetrin), and some of these substances have a
proven biological activity (Facundo et al., 1993).
Although Combretum leprosum is popularly used as a medicinal
plant to treat skin problems and lesions (Facundo et al., 2005),
there is no scientiﬁc data proving the effectiveness of its possible
topical anti-inﬂammatory activity. Thus, in this study, we used
classical models of skin inﬂammation such as TPA- and croton oil-
induced mouse ear oedema, in order to verify the potential topical
anti-inﬂammatory activity of the ethanolic extract (EE) from
ﬂowers of Combretum leprosum.2. Material and methods
2.1. Plant material and preparation of EE
Botanical material was collected in May 2007 at Vic-osa, Ceara´
State, Brazil, and was classiﬁed by Dr. Afraˆnio Fernandes (Universi-
dade Federal do Ceara´, Fortaleza) as Combretum leprosum Mart. A
voucher specimen of this plant was deposited in the Herbarium
Prisco Bezerra of the Biology Department, Universidade Federal do
Ceara´, Brazil, under number 12446 (May 2007). The dried ﬂowers
(2.7 kg) were powdered and extracted using ethanol (5 L), which was
stirred and macerated at room temperature (2473 1C) for approxi-
mately 24 h. This procedure was repeated three times. The solvent
was fully evaporated under reduced pressure, and the extract (yield
58.3 g) was lyophilised and stored in a freezer at 20 1C until use.2.2. Drugs and reagents
The following drugs were used to execute the experimental
protocols: 12-O-tetradecanoylphorbol-acetate (TPA), croton oil,
arachidonic acid (AA), indomethacin, dexamethasone, tetra-
methylbenzidine (TMB), 4-nitrophenyl N-acetyl-b-D-glucosami-
nide, hexadecyltrimethylammonium bromide (HTAB), Triton-X,
mifepristone and 3-(4,5-dimetylyhiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), (all from Sigma Chemical Co, St Louis MO),
dimethylformamide, acetone, formaldehyde, glacial acetic acid,
phosphate-buffered saline (PBS), parafﬁn (all from Merck Bios-
ciences, Germany), bovine serum albumin, Cohn fraction V (BSA)
(Inlab, Brazil), hydrogen peroxide, absolute ethanol, methanol,
eosin, sodium acetate, glycine, hematoxylin and xylene (all from
Vetec, Rio de Janeiro, Brazil). Dulbecco’s modiﬁed Eagle’s medium
(DMEM) and foetal bovine serum were obtained from Cultilab
(Brazil).
2.3. Animals
Experiments were performed on female Swiss mice (25–35 g)
which were housed in an animal room under conditions of
2272 1C, and a 12-h light/dark cycle, with free access to food
and water. The animals were allowed to adapt to the laboratory
for at least 1 h before testing and were used only once. All animal
procedures were performed after approval of the protocol by the
Institutional Ethics of our University (protocol number 296) and
were carried out in accordance with current guidelines for the
care of laboratory animal.
2.4. Irritative contact dermatitis models
Skin dermatitis was induced by TPA or AA and the inﬂamma-
tory response was evaluated through oedema formation. Oedema
was expressed as the increase in mice ear thickness (mm). Ear
thickness was assessed near the medial edge of the ear by using a
digital micrometer (MT-045B, Shangai Metal Great Tools Co., Ltd.,
Shangai, China). Measures were taken before and after induction
of the inﬂammatory process. The phlogistic agents were dissolved
in 20 mL of acetone while the extract was dissolved in 20 mL
of ethanol-acetone (3:7 v/v) and applied to the right ear of
each mouse.
Oedema was induced by topical application of TPA (2.5 mg/ear)
or AA (2 mg) in the right ear of the mice. Plant extract (0.01–
1.0 mg/ear) and dexamethasone (0.1 mg/ear) or indomethacin
(2 mg/ear) were applied as reference drugs immediately after
the phlogistic agents in experimental groups. To verify the
possible involvement of glucocorticoid receptors, animals were
pre-treated with mifepristone (50 mg/kg, s.c.) dissolved in poly-
ethylene glycol 400, 15 min prior to EE (0.6 mg/ear) or dexa-
methasone (0.001 mg/ear). Ear thickness was measured before
and 6 or 1 h after challenge with TPA or AA, respectively. Ear
samples (6 mm circles of tissue) were collected 24 h after the
application of TPA and subjected to histological analysis and
assessment of the enzyme myeloperoxidase (MPO) activity and
interleukin (IL)-6 tissue levels.
2.5. Croton oil-induced chronic skin inﬂammation
The chronic inﬂammatory process was induced by application
of croton oil (0.4 mg/ear) on alternate days for nine days. The
extract (0.6 mg/ear) and dexamethasone (0.1 mg/ear, positive
control), were administered from the ﬁfth day of the trial and
applied topically for the last four days (twice a day). On the ninth
day of the experiment, the animals were sacriﬁced and 6 mm
circles of ear tissue were collected, weighed and submitted to the
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Fig. 1. Effect of ethanolic extract from Combretum leprosum (EE) and dexametha-
sone (Dexa) administered topically on TPA-induced ear oedema (a) and myelo-
peroxidase activity in supernatants of homogenates from TPA-treated ears (b). Ear
oedema and MPO activities were measured at 6 and 24 h after TPA treatment,
respectively. All tested drugs were applied after TPA application. Each bar
represents the mean7S.E.M. for 5–10 animals. The graphic symbols denote the
signiﬁcance levels when compared with control groups. Signiﬁcantly different
from controls, nPo0.05, nnPo0.01 and nnn and ###Po0.001.
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activities, as well as histological analysis.
2.6. MPO and NAG enzyme activity assay
To assess enzyme activity, the methodology of Bradley et al.
(1982) modiﬁed by De Young et al. (1989) was used. The biopsies
(6 mm circles of tissue) were added to 0.75 mL of 80 mM PBS pH
5.4 containing 0.5% of HTBA, and were homogenised (45 s at 0 1C)
in a motor-driven homogeniser. The homogenate was decanted
into microtubes and added to 0.75 mL of buffer, as previously
described. The samples (1.5 mL) were placed in microfuge tubes
and centrifuged at 11,200g at 4 1C for 20 min. MPO activity was
achieved with triplicates of 30 mL of the supernatant placed on
96-well plates, where 200 mL of a mixture containing 100 mL of
80 mM PBS pH 5.4, 85 mL of 0.22 M PBS pH 5.4 and 15 mL of
0.017% hydrogen peroxide was subsequently added into each
well. The addition of 20 mL of 18.4 mM TMB in dimethylforma-
mide promoted the start of the reaction. The plate was then
incubated at 37 1C for 3 min and the reaction was stopped by the
addition of 30 mL of 1.46 M sodium acetate, pH 3.0. NAG activity
was reached with triplicates of 25 mL of supernatant placed on
96-well plates, followed by the addition of 100 mL of 50 mM
citrate buffer, pH 4.5. The reaction was initiated by the addition of
25 mL of 2.24 mM 4-nitrophenyl N-acetyl-b-D-glucosaminide. The
plate was incubated at 37 1C for 1 h and the reaction was stopped
by the addition of 30 mL of 200 nM glycine buffer, pH 10.4. The
enzymatic activity was determined colourimetrically using a
plate reader (EL808; BioTech Instruments, INC) set to measure
absorbance at 630 nm for MPO or 405 nm for NAG. The results are
expressed as mOD/mg tissue.
2.7. Measurement of IL-6 levels
Amounts of IL-6 in homogenates of ear tissue samples were
quantiﬁed using a mouse IL-6 ELISA kit (eBioscience, San Diego,
USA) according to the manufacturer’s instructions. Levels of this
cytokine in each supernatant were normalised to total protein
content, which was determined using a Bio-Rad Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA).
2.8. Histological assessment of skin tissue
Ear samples were ﬁxed in a solution containing ethanol 80%,
formalin 40%, and glacial acetic acid (ALFAC solution). The ears
were subsequently embedded in parafﬁn, sectioned to 5 mm and
stained with hematoxylin–eosin. The inﬁltration of leukocytes
and epidermis thickness were evaluated in representative areas
selected with 10 and 40 objectives. The quantiﬁcation of
leukocytes in the dermis was performed by counting these cells
per ﬁeld, and ﬁve ﬁelds from three distinct histological sections of
each group were analysed. To reduce the probability of error, the
researcher did not know which group he was investigating.
2.9. Immunohistochemical evaluation of proliferating cell nuclear
antigen (PCNA) levels
Sections (5 mm) of tissue previously ﬁxed in ALFAC and
embedded in parafﬁn were placed onto silanised glass slides and
deparafﬁnised twice with xylene, followed by rehydration through a
graded alcohol bath. To block radical aldehyde, each section was
treated with glycine (0.1 M) and with 3% hydrogen peroxide in
methanol to block endogenous peroxidase. Slices were treated with
1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS)
to diminish non-speciﬁc staining. For the detection of PCNA, slides
were incubated with 1:50 dilutions of a polyclonal anti-PCNAantibody (Santa Cruz Biotechnology, Inc, USA) in PBS/BSA 1% at
room temperature in a moist chamber for 2 h and washed with
PBS/BSA 1%. Subsequently, the sections were incubated using a
secondary antibody IgG HRP (Santa Cruz Biotechnology, Inc, USA)
diluted 1:50 in PBS/BSA 1% at room temperature in a moist chamber
for 1 h. The peroxidase-binding sites were detected by staining with
DAB substrate Kit (BD Bioscience, California, USA), and incubating
for 15 min. Finally, slices were counterstained with Mayer’s hema-
toxylin and then dehydrated and mounted.
2.10. Cell culture
The human keratinocyte cell line HaCaT was cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10%
foetal bovine serum and 1% penicillin/streptomycin (10,000 U/
100 mg/ml) at 37 1C with 5% CO2 in a humidiﬁed atmosphere.
2.11. Cell proliferation assay
HaCaT cells (7103) were seeded in each well of a 96-well
plate and incubated at 37 1C for a period of 24 h. The media were
then replaced with 200 ml of fresh media containing varying
concentrations of EE (5, 10, 15, 20, 25 and 30 mg/mL). The plate
was then re-incubated, maintaining the same conditions, for
24, 48 and 72 h, after which cell viability and cell density were
veriﬁed by MTT and CyQuant assays, respectively. Following
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at 37 1C for 4 h. After removing the supernatant, 150 mL of ethanol
was added to each well to dissolve formazan crystals, and optical
density was detected at 470 nm using a plate reader (EL808B,
BioTech Instruments, Inc., Winooski, VT, USA). Cell density was
estimated using a cell proliferation assay (CyQuant kit; Invitrogen
Molecular Probes), which relies on a ﬂuorescent dye, and exhibits
a strong increase in ﬂuorescence when bound to DNA. Following
incubation, the medium was removed and the plate was frozen at
70 1C. 200 mL of the CyQuant dye-cell lysis buffer was then
incubated for 2–5 min at room temperature and the ﬂuorescence
intensity, which was related to the number of cells present, was
measured at 485/535 nm.
2.12. Statistical analysis
The results were expressed as mean7S.E.M., except for the
ID50 values (dose required to reduce by 50% the responses of the
groups treated relative to the control group), which wereVehicle Control
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Fig. 2. Representative pictures of histological sections from mice ears stained with hem
of leukocytes (f). (a) vehicle, (b) control, (c) treatment with ethanolic extract from Co
indicate the inﬁltrated leukocytes. Each bar represents the mean7S.E.M. for 3–4 section
groups. Signiﬁcantly different from controls, nnn and ###Po0.001.represented as the geometric mean accompanied by their 95%
conﬁdence intervals. Data were evaluated by one-way analysis of
variance (ANOVA) followed by the Newman–Keuls post-hoc test
when appropriate. Po0.05 was considered as indicative of
signiﬁcance. The values were obtained using the Statistical soft-
ware GraphPad Prism version 3.00, San Diego California, USA.3. Results
Topical application of TPA promoted an increase in the thick-
ness of the ear and in the tissue MPO activity, while EE applied
topically alone did not alter any of these parameters (data not
shown). However, EE caused a dose-dependent inhibition of both
of the inﬂammatory parameters, oedema and cell migration,
induced by TPA (Fig. 1). EE presented an ID50 value of 0.11
(0.10–0.13) and 0.13 (0.11–0.16) mg/ear and the maximal inhibi-
tions observed at a dose of 1 mg/ear were 9672% and 9772% for
the oedema and MPO activity, respectively, (Fig. 1a and b). In******
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ear) showed inhibition values of 9771% and 9970.3% for
oedema and MPO activity, respectively.
Fig. 2 shows the analysis of HE-stained ear sections from TPA-
treated mice. TPA application resulted in a marked increase in ear
thickness, with clear evidence of oedema, and substantial inﬂamma-
tory cell inﬁltration in the dermis (Fig. 2b). EE treatment remarkably
reduced cell inﬁltration with an inhibition of 9672% (Fig. 2c), which
was comparable to the positive control dexamethasone to an extent,
(Fig. 2d) which showed an inhibition of 100.070.4%.
Levels of IL-6 in skin tissue were signiﬁcantly higher in ears
submitted to TPA application as compared to naı¨ve or vehicle
(acetone) groups (Fig. 3). EE treatment promoted a decrease of
IL-6 concentration with a maximum inhibition of 93.473.8%
(0.3 mg/ear), while dexamethasone inhibited the cytokine con-
centration by 66.4710.1%.
Topical application of AA promoted rapid and intense inﬂam-
matory response, as veriﬁed by oedema formation. Topical EE
treatment inhibited oedema formation in all of the testedNaive Vehicle Control 0.03 0.1 0.3 1.0 0.1
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Fig. 3. Interleukin-6 levels in supernatants of homogenates from TPA-treated ears
after treatment with EE (0.03–1.0 mg/ear) or dexamethasone (0.1 mg/ear). Mea-
surements were performed with a commercial ELISA kit. Each bar represents the
mean7S.E.M. for 3–4 sections. The graphic symbols denote the signiﬁcance levels
when compared with control groups. Signiﬁcantly different from controls,
nnPo0.01 and ###Po0.001.
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Fig. 4. Effect of ethanolic extract from Combretum leprosum (EE) and indometha-
cin (Indo) administered topically on AA-induced ear oedema. Ear oedema was
measured 1 h after AA treatment. All tested drugs were applied after AA
application. Each bar represents the mean7S.E.M. for ﬁve animals. The graphic
symbols denote the signiﬁcance levels when compared with control group.
Signiﬁcantly different from control nnnPo0.001.concentrations with a maximum inhibition of 7272% (1.0 mg/ear),
while the reference drug, indomethacin, promoted inhibition of
8274% (Fig. 4).
As shown in Fig. 5a, both the EE and dexamethasone treat-
ments were able to revert the oedema formation even after the
establishment of the inﬂammatory process, which was shown by
the ear weight, evaluated on the ninth day, presenting an
inhibition of 6373% and 7772%, respectively.
Histological analysis enabled the assessment of some para-
meters, such as hyperproliferation of epidermal keratinocytes.Vehicle Control EE Dexa
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Fig. 5. Effect of ethanolic extract from Combretum leprosum (EE) and dexametha-
sone (Dexa) administered topically on croton oil-induced ear oedema (a), MPO
activity (b) and NAG activity (c) in supernatants of homogenates from croton oil-
treated ears. Croton oil was applied on alternate days for nine days and the tested
drugs were applied after the ﬁfth day for four days, twice a day. Ear oedema and
enzymatic activities were measured on the ninth day of croton oil treatment.
In the vehicle animal (V), only acetone was applied. Each bar represents the
mean7S.E.M. for 5–10 animals. The graphic symbols denote the signiﬁcance
levels when compared with control groups. Signiﬁcantly different from controls,
nn and ##Po0.01 and nnn and ###Po0.001.
C.D.S. Horinouchi et al. / Journal of Ethnopharmacology 145 (2013) 311–319316Multiple applications of croton oil promoted an increase of
epidermis thickness by approximately ﬁve times that of the
control (Fig. 6). Both EE and dexamethasone applications were
effective in reducing the epidermal hyperproliferation by 5074%
and 7072%, respectively (Fig. 6f).
Concerning neutrophil migration in the chronic skin inﬂam-
mation, the treatment with EE was not able to modify MPO
activity (Fig. 5b), unlike dexamethasone, which promoted the
complete inhibition of enzyme activity. However, EE inhibited
NAG activity, like dexamethasone, causing a reduction in 7674%
and 8375%, respectively (Fig. 5c). Inhibition of cell inﬁltration
was conﬁrmed by the quantiﬁcation of leukocytes in the dermis
through histological analysis, and EE and dexamethasone treat-
ments were able to reduce the quantity of cells in 6174% and
74710%, respectively (Fig. 6e).
As depicted in Fig. 7, PCNA-positive cells were detected in all
groups. However, the vehicle group demonstrated few labelled
cells as an indication of a normal basal proliferation activity
(Fig. 7a). The challenge with repeated croton oil treatment
promoted an increase in the number of proliferative cells, withVehicle Control
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Fig. 6. Representative pictures of histological sections from mice ears stained with
quantiﬁcation of leukocytes (e) and measurement of epidermis thickness (f). (a) vehicl
(0.6 mg/ear), (d) dexamethasone (0.1 mg/ear). Arrows indicate the epidermis and arrow
3–4 sections. The graphic symbols denote the signiﬁcance levels when compared withsome of these proliferative cells being observed outside of the
basal layer (Fig. 7b). The epidermis hyperproliferation induced by
croton oil was signiﬁcantly reduced by treatment with EE, as well
as with dexamethasone, presenting a decrease of PCNA-positive
cells in 27712% and 6576%, respectively (Fig. 7c and d). More-
over, an anti-proliferative effect was also observed in cultured
HaCaT keratinocytes, as determined by MTT and CyQUANT assays
(Fig. 8). EE reduced cell viability, which was shown by an increase
in the efﬁcacy at higher concentrations and a slight increase with
the higher duration of exposure. At the higher concentration of
30 mg/mL, an efﬁcacy of 93.172.7% was observed after 72 h of
incubation. Similar results were achieved with the CyQUANT cell
proliferation assay, where EE reduced the cell density at higher
concentrations and longer durations of exposure. After 72 h of
incubation, the higher concentration (30 mg/mL) showed an
efﬁcacy of 96.873.2%.
In an attempt to verify a possible mechanism of action, mife-
pristone, a glucocorticoid receptor antagonist, was applied before
treatments. Pre-treatment with the antagonist was able to abolish
the anti-oedematogenic effect of EE and dexamethasone (Fig. 9).Vehicle Control
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The present work provides evidence that ﬂowers of Combretum
leprosum possess an anti-inﬂammatory effect when topically
applied to the skin. As ﬁrst evidence, EE demonstrated efﬁcacy
at reducing inﬂammatory parameters, such as oedema and cell
migration, in a dose-dependent manner in the model of TPA-
induced ear oedema. TPA is a phorbol ester, which, once topically
applied, promotes an acute inﬂammatory response that displays
vasodilation, polymorphonuclear leukocyte tissue inﬁltration and
oedema formation. All of these events appear to arise from the
direct activation of protein kinase C (PKC) which promotes an
increase in activity of the enzyme phospholipase A2 (PLA2),
increasing the levels of arachidonic acid and its metabolites, such
as prostaglandins and leukotrienes. These metabolites, as well
as cytokines, are mediators of inﬂammatory pathways, and are
responsible for triggering and maintaining inﬂammation (Stanley
et al., 1991). Thus, the constituents of the Combretum leprosumextract are probably negatively interacting with molecules such as
cytokines in some of these steps during the formation of oedema,
and can therefore be targets for the development of new topical
anti-inﬂammatory therapeutic agents.
Inﬂammatory skin diseases are usually characterised by
intense neutrophil inﬁltration, which are cells that are considered
the ﬁrst line of defence against pathogens. Neutrophils possess
rich machinery, containing mainly reactive oxygen species (ROS),
which are capable of degrading pathogen proteins. This defence
system is harmful not only to pathogens, but can also have a
detrimental effect on components of host tissues (Nemeth and
Mocsai, 2012). Although polymorphonuclear cells (PMNs) are
particularly involved in acute inﬂammatory responses, in some
chronic immune diseases, such as psoriasis, there is an important
accumulation of PMN. Neutrophils in psoriatic lesions secrete
cytokines, proteolytic enzymes and ROS, which can stimulate
T cells and keratinocytes to maintain an inﬂammation-sustaining
loop (Terui et al., 2000). Thus, compounds which are able to
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Fig. 8. Effect of ethanolic extract from Combretum leprosum (EE) on the viability and
proliferation of HaCaT cells. HaCaT cells were exposed to EE (0–30 mg/mL) and
incubated for 24, 48 or 72 h. For cell viability, surviving cells were measured byMTT
assay (a). Cell density was measured by CyQUANT Cell Proliferation Assay (b).
Results were expressed as the percentage of the control group (0—receiving just
fresh medium). The graphic symbols denote the signiﬁcance levels when compared
with control groups. Signiﬁcantly different from controls, nPo0.05, nnPo0.01 and
nnnPo0.001.
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Fig. 9. Reversal of the anti-oedematogenic activity of EE and dexamethasone by
mifepristone. EE and dexamethasone was applied immediately after TPA. Mife-
pristone (50 mg/kg s.c.) was administered 15 min prior to EE (0.6 mg/ear) or
dexamethasone (0.001 mg/ear). Each bar represents the mean7S.E.M. for ﬁve
animals. The graphic symbols denote the signiﬁcance levels when compared with
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parameters and are potential anti-inﬂammatory tools. MPO is
known as a direct marker of neutrophil inﬁltration; therefore, the
inhibition of its activity can be used as an indicator of anti-
inﬂammatory action (Bradley et al., 1982). In our results, it was
evidenced that EE was able to decrease the activity of this
enzyme, suggesting possible interference in cell migration during
the inﬂammatory process. The histological analysis clearly con-
ﬁrmed that EE, like dexamethasone, inhibited the TPA-induced
inﬂux of PMN to the mouse ear skin.
Another evidence of the EE anti-inﬂammatory activity in the
acute inﬂammatory model was the reduction of IL-6 tissue levels.
IL-6 is rapidly expressed during an inﬂammatory stimulus and acts
synergistically with IL-1 and Tumor Necrosis Factor-a in promoting
and maintaining acute inﬂammatory processes. In addition, IL-6 is a
modulator of the switch from innate to adaptative immune response
thus the reduced level of IL-6 promoted by EE could justify, at least
in part, the inhibition of leukocyte tissue inﬁltration in the EE-
treated tissue. (Scheller et al., 2011). Actually, it is clear that defects
in the normal IL-6 activity are noticed in the pathogenesis of a
number of inﬂammatory disorders, especially autoimmune diseases.
However, increased levels of this cytokine are usually observed in
patients with psoriasis and other immune disorders (Ishihara and
Hirano, 2002). Nowadays, the blockade of the IL-6 pathway has been
considered an interesting target for the treatment of autoimmune
diseases. Therefore, in the research for the development of therapies
based on IL-6 downregulation, the current challenge is to establish
how to interfere with this pathway, and in which conditions it
would be beneﬁcial (Jones et al., 2011).
A time-course evaluation of anti-oedematogenic topic activ-
ity of the EE showed a long-lasting effect for at least twelve
hours (data not shown). Combretum leprosum extract seems
to act as a prophylactic agent and, most importantly, as a
potential option for treatment after the establishment of the
inﬂammatory process, since it was effective even when applied
three hours after the TPA stimulus. These results suggested that
the extract could be effective in pre-established inﬂammatory
processes. Thus, the model of multiple applications of croton oil
allowed the evaluation of the EE in a pre-existent inﬂammatory
process. This model is a reliable tool to assess the response of
anti-inﬂammatory and anti-proliferative compounds on an
established chronic inﬂammatory skin process, characterised
by an increase in tissue (ears) weight, intense cell inﬁltration,
and epidermal hyperproliferation (increasing in epidermis mea-
surement with development of acanthosis). These events are
similar to those observed in some chronic inﬂammatory skin
diseases like psoriasis (Stanley et al., 1991). Skin inﬂammation
is a prominent pathological feature of psoriasis, which is
characterised immunologically by the migration and accumula-
tion of neutrophils and mononuclear cells in the epidermis.
Indeed, this condition shows a marked thickening of this layer,
due to the uncontrolled proliferation of keratinocytes, also
presenting thin downward projections into the dermis. In
addition, there is marked inﬁltration of mononuclear leukocytes
in the dermis, which can gain entry to skin parenchyma by
transmigration through reactive vessels (Lowes et al., 2007).
Therefore, in the model of chronic applications of croton oil, the
EE of Combretum leprosum was able to reduce all inﬂammatory
parameters evaluated, such as oedema, cell migration and
epidermal hyperproliferation.
In chronic inﬂammation animal models, the major type of
inﬁltrated cells are mononuclear, which are evaluated through of
the measurement of the activity of the enzyme N-acetyl-b-D-
glucosaminidase (NAG). When activated, mononuclear cells
degranulate and sequentially promote the release of inﬂamma-
tory mediators, including cytokines, chemokines, as well as lipid
C.D.S. Horinouchi et al. / Journal of Ethnopharmacology 145 (2013) 311–319 319mediators, that work together to promote the recruitment and
activation of other inﬂammatory cells (Lawrence and Gilroy,
2007). Thus, by inhibiting mononuclear cell migration the extract
can contribute to the relief of symptoms trigged by those
inﬂammatory cells and mediators, which is an important deleter-
ious mechanism of chronic inﬂammatory diseases. Last but not
least, EE topical treatment was also able to inhibit the epidermal
hyperproliferation induced by croton oil. Since the hallmarks of
psoriasis lesions are plaques covered with silvery scales generated
by hyperproliferation and altered differentiation of epidermal
keratinocytes (Wolf et al., 2012), the efﬁcacy of EE in reducing
this occurrence suggests a potential option to treat skin diseases
such as psoriasis and seborrheic dermatitis. In addition, our
results from in vitro experiments showed that EE substantially
reduced the proliferation of keratinocytes, which are the main
cellular type involved in psoriasis pathogenesis. This effect
demonstrates that the extract does not reduce the proliferation
of epidermal cells indirectly just by inhibiting tissue inﬂamma-
tion, but also act directly in the epidermal cell viability.
Pre-treatment with the glucocorticoid receptor antagonist
mifepristone reversed the inhibitory effect of EE and dexametha-
sone on TPA-induced ear oedema, suggesting a glucocorticoid-like
effect for EE. Interaction with glucocorticoid receptors could
explain both the anti-inﬂammatory and antiproliferative effects
of EE, since glucocorticoids are known as great anti-proliferative
and anti-inﬂammatory agents, and are extensively used in anti-
psoriatic therapy.
In view of the fact that the Brazilian population uses
Combretum leprosum as a topical remedy for wound healing and
snake bites, based on this preliminary study using in vivo animal
models of skin inﬂammation, it is possible to sustain its folk
usage; since Combretum leprosum reduced inﬂammatory para-
meters in acute model it is possibly able to alleviate symptoms of
skin injuries. In summary, these results suggest that Combretum
leprosum can be effective as an anti-inﬂammatory when topically
applied, even though the molecular mechanism whereby Com-
bretum leprosum acts has not been completely identiﬁed. How-
ever, it is necessary to continue the investigations regarding this
plant and its compounds to demonstrate its effectiveness, safety,
and elucidate the mechanism of action.Acknowledgments
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